

**Supplementary Table 2.** Input parameters (costs and utility weights)

Parameter	Value	Reference
Costs		
Screening & lab test (USD)		2
Screening (HCV antibody)	3.91	
HCV RNA	111.50	
Genotyping	127.32	
CBC	6.42	
LFT	7.99	
Consult fee: new patient	15.20	
Consult fee: established patient	11.45	
Monitoring*	437.95	
Drug cost (USD)		
DAA <sup>†</sup>	9,252.33	3
Glecaprevir/pibrentasvir (8 weeks)	9,255.37	
Sofosbuvir+ribavirin (12 weeks)	9,165.18	
Elbasvir/grazoprevir (12 weeks)	9,256.36	
Ledipasvir/sofosbuvir (12 weeks)	9,255.51	
Annual medical cost (USD)		
F0–F3	472.35 (425.12–519.59) <sup>‡</sup>	KNHIS claim data
F4	532.60 (479.34–585.86) <sup>‡</sup>	KNHIS claim data
DC	8,487.37 (1603.15–15371.59)	SNUBH administrative data
HCC	10,972.06 (4585.59–17358.54)	SNUBH administrative data
LT	79,653.85 (71688.47–87619.24) <sup>‡</sup>	KNHIS claim data
Post-LT	7,732.57 (6959.31–8505.83) <sup>‡</sup>	KNHIS claim data
SVR from F0–F3	0	Assume as 0
SVR from F4	177.78	The national health screening program fee
Non-direct medical cost (USD)		
Transportation & time cost		4-8
F0–F3	161.14	
F4	215.7	
DC	817.69	
HCC	1,069.84	
LT	2,182.81	
Post-LT	161.14	Assume same as F0–F3
SVR from F0–F3	0	Assume as 0
SVR from F4	123.6	
Indirect cost (productivity loss cost due to HCV-related deaths) (USD)		
Age 40–49 years	241,002–360,622	8,9
Age 50–59 years	54,197–225,872	
Age 60–64 years	6,698–43,177	

**Supplementary Table 2.** Continued

Parameter	Value	Reference
Utility		10-13
Utility weight		
F0–F3	0.854 (0.79–0.88)	
F4	0.737 (0.69–0.78)	
DC	0.671 (0.56–0.69)	
HCC 1st year	0.675 (0.675–0.72)	
HCC over 2nd year	0.428 (0.25–0.675)	
LT	0.6 (0.5–0.75)	
Post-LT	0.75 (0.7–0.95)	
SVR	0.894 (0.83–0.92)	
SVR-F4	0.777 (0.73–0.84)	

Values are presented as mean (range).

HCV, hepatitis C virus; CBC, complete blood cell count; LFT, liver function test; DAA, direct acting antiviral; KNHIS, Korean National Health Insurance Service; DC, decompensated cirrhosis; SNUBH, Seoul National University Bundang Hospital; HCC, hepatocellular carcinoma; LT, liver transplantation; SVR, sustained virological response.

\*LFT × 4 + CBC × 4 + HCV RNA test × 3 + consultation fee (for established patient) × 4.

<sup>†</sup>Weighted average value by the distribution of DAA use (2019 data from Korean HCV cohort study).

<sup>‡</sup>Out-of-pocket money paid by patients was added since it was not covered by the NHIS (average proportion in 2019: 16.6%).<sup>14</sup> It was also adjusted for inflation using the Korean consumer price index to reflect the 2020 KRW.<sup>15</sup>